Patient


  • magic wand
    Image attribution tooltip
    Stock via Getty Images
    Opinion

    What would you fix with a ‘magic wand’? Pharma leaders chime in about clinical trials

    How life science execs would transform clinical trials with a little hocus pocus.

    By PharmaVoice staff • March 24, 2023
  • High angle shot of people reaching to connect puzzle pieces together
    Image attribution tooltip
    Stock via Getty Images

    Everyone says they’re patient-centric, but have they really walked the walk?

    Life science leaders provide practical tips on how to create a sustainable patient-focused culture.

    By March 23, 2023
  • test tube gene Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Trendline

    Cell and gene therapies

    How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.

    By PharmaVoice staff
  • wuhan
    Image attribution tooltip
    Getty via Getty Images

    Viral roots: A look at how modern outbreaks began

    As experts wrestle with COVID-19’s lab leak versus animal market debate, here’s what experts say are the suspected origins for some of the worst viral outbreaks in the last century.

    By March 22, 2023
  • Magical, illuminated mushroom growing on a moss
    Image attribution tooltip
    Stock via Getty Images

    ‘The Last of Us’ might be fiction, but fungi are a looming threat

    Fungal infections are a growing challenge for hospitalized patients, and new treatments are badly needed.

    By Kelly Bilodeau • March 20, 2023
  • Nobel Peace Prize
    Image attribution tooltip
    Chris Jackson/Getty Images via Getty Images

    A biopharma CEO’s quest for global health equity has put him in the running for a Nobel Prize

    Dr. Ryan Saadi, CEO of Tevogen Bio, is making good on a lifelong goal of bringing T cell therapies to people who need them.

    By March 17, 2023
  • A glass building with a sign that reads,  "Biogen."
    Image attribution tooltip

    Paul Marotta/Sipa USA/Newscom

    Making Moves

    In the fallout from Aduhelm, Biogen’s leadership shakeup continues

    The recent departure of neurodegenerative development head Samantha Budd Haeberlein is just the latest sign of a changing tide among Biogen’s post-Aduhelm leadership.

    By March 16, 2023
  • hands connecting healthcare
    Image attribution tooltip
    Stock via Getty Images
    Profile

    The power of connections for a startup CEO

    Priyanka Dutta-Passecker, head of wound-care specialist Healiva, discusses the importance of tapping her network in starting and running a biotech.

    By Alexandra Pecci • March 14, 2023
  • Babson Diagnostics
    Image attribution tooltip
    Permission granted by Babson Diagnostics
    Q&A

    Babson aims to shed Theranos curse with new blood testing tech

    Babson Diagnostics is trying to create a less invasive blood testing technology — can it gain trust in the post-Theranos era?

    By Kelly Bilodeau • March 13, 2023
  • Pharmacist talking with customer about medicine bottle in drugstore.
    Image attribution tooltip
    simonkr via Getty Images
    Sponsored by GoodRx

    Across therapy areas, GoodRx’s POS rebates improve access and affordability for cash-paying patients

    Across therapy areas, GoodRx Assist is a proven point-of-sale rebate program for cash-paying patients.

    March 13, 2023
  • Murray Aitken IQVIA Institute
    Image attribution tooltip
    Permission granted by Murray Aitken/IQVIA Institute
    Q&A

    IQVIA’s OG of data analytics on the latest clinical trial trends

    IQVIA Institute’s Murray Aitken is the man behind the numbers, and here, shares the newest findings on clinical trial burnout, diversity and more.

    By March 10, 2023
  • Senior older women
    Image attribution tooltip
    Stock via Getty Images

    Targeting the new ‘Golden Girls’

    With unprecedented buying power, women over 50 wield a lot of influence — but are still underserved by pharma. Urovant hopes to change that with its potential blockbuster drug.

    By March 8, 2023
  • storytelling marketing
    Image attribution tooltip
    Stock via Getty Images

    3 keys to good storytelling in pharma

    The CEO of Complement Therapeutics shares simple storytelling tactics lead to maximum impact.

    By Alexandra Pecci • March 7, 2023
  • silhouette people
    Image attribution tooltip
    Stock via Getty Images

    PharmaVoice 100 honorees: Where are they now?

    How some of our past PharmaVoice 100 honorees are transforming the life sciences industry in new roles. 

    By , March 3, 2023
  • drug injection cost
    Image attribution tooltip
    Stock via Getty Images

    Multimillion-dollar therapies are changing how payers foot the bill

    With more gene therapies headed to market, novel payment methods are emerging from regulators and academia. 

    By Feb. 28, 2023
  • A sign for the Food and Drug Administration is seen on July 20, 2020 in Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images

    Reata’s stock plummets amid sudden FDA neuro office shakeup

    The FDA’s longtime neuroscience head Billy Dunn stepped down, leaving industry reeling over how the agency’s new acting director could handle upcoming approval decisions.

    By Feb. 28, 2023
  • patient care
    Image attribution tooltip
    Stock via Getty Images
    Q&A

    Why patient care is a public affair

    The VP of public affairs at Kyowa Kirin discusses her role in advocating for advocacy.

    By Feb. 23, 2023
  • Will Chou headshot
    Image attribution tooltip
    Permission granted by Dr. William Chou, Passage Bio
    Q&A

    Managing for resilience: Passage’s ups and downs in gene therapy

    After a rocky year, Passage Bio’s CEO is focused on helping the rare disease specialist bounce back.

    By Feb. 15, 2023
  • Ester Banque Bristol Myers Squibb
    Image attribution tooltip
    Permission granted by Ester Banque Bristol Myers Squibb
    Podcast

    Woman of the Week: Bristol Myers Squibb’s Ester Banque

    The 30-year veteran is heading up the “transformation” of one of the pharma giant’s most important therapeutic portfolios: hematology.

    By Feb. 15, 2023
  • Multicolored wave lines in the shape of an eye
    Image attribution tooltip
    Stock via Getty Images
    Profile

    For Complement’s CEO, storytelling could be just as critical as data

    Dr. Rafiq Hasan has his sights on bringing lessons learned at Bayer to ophthalmology-focused Complement Therapeutics.

    By Alexandra Pecci • Feb. 14, 2023
  • mental health concept
    Image attribution tooltip
    Stock via Getty Images

    Why are there gaps in mental healthcare? Often it’s flawed trial methodology

    Sunovion Pharmaceuticals has developed a more precise way to track symptoms that could be broadly adopted across the industry.

    By Kelly Bilodeau • Feb. 10, 2023
  • Professional headshot of Tamar Thompson
    Image attribution tooltip
    Permission granted by Alexion
    Profile

    United by inequity: The healthcare disparities plaguing rare disease patients and Black Americans

    Guided by her personal experiences, Tamar Thompson is aiming to improve rare disease care through her advocacy work at Alexion, AstraZeneca Rare Disease.

    By Alexandra Pecci • Feb. 7, 2023
  • Yesmean Wahdan Bayer
    Image attribution tooltip
    Permission granted by Yesmean Wahdan Bayer
    Podcast

    Woman of the Week: Bayer’s Dr. Yesmean Wahdan

    The VP of medical affairs and women’s health is focused on an audacious goal to meet the needs of 100 million women globally.

    By Feb. 1, 2023
  • Teens in circle holding smart mobile phones of different colors.
    Image attribution tooltip
    Stock via Getty Images

    Patients are using social media — clinical trial experts can learn from that

    Why an alliance of industry leaders is exploring the potential of social media as a treasure trove of real-world patient experience insights. 

    By Jan. 30, 2023
  • Ira Spector SFA Therapeutics
    Image attribution tooltip
    Permission granted by Ira Spector SFA Therapeutics
    Profile

    A biotech CEO’s favorite ‘F’ word

    At SFA Therapeutics, patients are the “focus” of Ira Spector’s approach to changing the course of autoimmune disease.

    By Jan. 26, 2023
  • Johanna Mercier headshot
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Q&A

    Gilead’s commercial chief on why 2023 will be a ‘coming out’ year

    With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.

    By Jan. 26, 2023